Tevogen Bio Stock (NASDAQ:TVGN)


OwnershipFinancialsChart

Previous Close

$1.08

52W Range

$0.26 - $3.09

50D Avg

$1.25

200D Avg

$1.06

Market Cap

$193.09M

Avg Vol (3M)

$1.88M

Beta

-0.82

Div Yield

-

TVGN Company Profile


Tevogen Bio Holdings Inc. operates as a clinical-stage biotechnology company that develops off-the-shelf precision T cell therapeutics in virology, oncology, and neurology. Its lead investigational precision T cell product, TVGN 489, is designed to address the unmet need of acute-risk COVID-19 patients, as well as a subset of patients suffering from long COVID. The company is based in Warren, New Jersey.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

18

IPO Date

Jan 05, 2022

Website

TVGN Performance


TVGN Financial Summary


Dec 24Dec 23Dec 22
Revenue---
Operating Income$-53.56M$-8.84K$-13.72M
Net Income$-13.73M$-67.33K$4.41M
EBITDA$-53.56M$188.71K$-953.08K
Basic EPS$-0.09-$0.04
Diluted EPS$-0.09-$0.04

Fiscal year ends in Dec 24 | Currency in USD